Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 3 1

Status

Completed 10Active not recruiting 7Recruiting 6Terminated 5Withdrawn 1Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 6Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 126Leukemia, Lymphocytic, Chronic, B-Cell 30Myelodysplastic Syndromes 27Leukemia 22Recurrence 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma 10Leukemia, Biphenotypic, Acute 8Hematologic Neoplasms 8Burkitt Lymphoma 8Leukemia, Myelomonocytic, Chronic 7Neoplasm, Residual 6Multiple Myeloma 6Lymphoma, Mantle-Cell 6Waldenstrom Macroglobulinemia 5Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma, B-Cell, Marginal Zone 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Myeloproliferative Disorders 4Leukemia, Myeloid 4Lymphoma, Large B-Cell, Diffuse 3Leukemia, Monocytic, Acute 3GATA2 Deficiency 3Sarcoma, Myeloid 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Immunoglobulin Light-chain Amyloidosis 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Anemia, Refractory, with Excess of Blasts 2

Interventions

Rituximab 20zanubrutinib 13acalabrutinib 11Magnetic Resonance Spectroscopy 11obinutuzumab 10Specimen Handling 10Cyclophosphamide 10Biopsy 9glofitamab 8Bendamustine Hydrochloride 8pirtobrutinib 7fludarabine 7venetoclax 6orelabrutinib 6ibrutinib 5Lenalidomide 5Cytarabine 5fludarabine phosphate 3Immunotherapy, Adoptive 3CT-P10 3tafasitamab 2polatuzumab vedotin 2loncastuximab tesirine 2brexucabtagene autoleucel 2Whole-Body Irradiation 2Therapeutics 2Prednisone 2Melphalan 2Maintenance 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, Mantle-Cell × venetoclax × Clear all
NCT05529069 2026-05-05

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

M.D. Anderson Cancer Center

Phase 2 Recruiting
30 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT03523975 2026-04-22

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

City of Hope Medical Center

Phase 1/2 Recruiting
28 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT05861050 2026-02-19

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

City of Hope Medical Center

Phase 1/2 Recruiting
50 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT04855695 2026-01-21

Avo In R/R And Previously Untreated MCL

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
72 enrolled
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT05910801 2024-11-18

V-MIND

Academic and Community Cancer Research United

Phase 2 Recruiting
100 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT06496308 2024-07-11

Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment

Ruijin Hospital

Phase 3 Recruiting
78 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡